Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer

JAMA

Volumn 293, Issue 9, 2005, Pages 1073-1081

  Muss, Hyman B ^a,l   Woolf, Susan ^b   Berry, Donald ^d   Cirrincione, Constance ^b   Weiss, Raymond B ^e   Budman, Daniel ^f   Wood, William C ^g,i   Henderson, I Craig ^j   Hudis, Clifford ^k   Winer, Eric ^h   Cohen, Harvey ^c   Wheeler, Judith ^b   Norton, Larry ^k  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b Cancer Leukemia Grp B Stat Ctr   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l FLETCHER ALLEN HEALTH CARE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FLUOXYMESTERONE; METHANOL EXTRACTION RESIDUE; METHOTREXATE; PACLITAXEL; PREDNISONE; TAMOXIFEN; THIOTEPA; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; LYMPH NODE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; AGE; AGED; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; LYMPH NODE METASTASIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 20044388527     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.9.1073     Document Type: Review

References (31)

1. Yancik R, Ries LA. Aging and cancer in America: demographic and epidemiologjc perspectives. Hematol Oncol Clin North Am. 2000;14:17-23.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-942.
3. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138:90-97.
4. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524-4531.
5. Lichtman SM, Skirvin JA. Pharmacology of anti-neoplastic agents in older cancer patients. Oncology (Huntingt). 2000;14:1743-1755.
6. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol. 1984;2:1404-1413.
7. Begg CB, Cohen JL, Ellerton J. Are the elderly predisposed to toxicity from cancer chemotherapy? an investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials. 1980;3:369-374.
8. Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest. 2000;18:521-529.
9. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: tolerance and outcome. Arch Intern Med. 1996;156:882-888.
10. Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. JAMA. 1992;268:57-62.
11. Levine MN, Bramwell VH, Pritchard KI, et al; National Cancer Institute of Canada Clinical Trials Group. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol. 1998;16:2651-2658.
12. Bonneterre JM, Roche H, Kerbrat P, et al. Long-term cardiac follow-up in free of disease patients (pts) after receiving 6 FEC 50 vs 6 FEC 100 (FASG-05 Trial) as adjuvant chemotherapy (CT) for node-positive (N+) breast cancer (BC). Proc Am Soc Clin Oncol. 2002;21: 39a.
13. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
14. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431-1439.
15. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-2067.
16. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20:2109-2117.
17. Weiss RB, Woolf SH, Demakos E, et al. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 2003;21:1825-1835.
18. Perloff M, Norton L, Korzun AH, et al. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996;14:1589-1598.
19. Budman DR, Berry DA, Cirrincione CT, et al; Cancer and Leukemia Group B. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998;90:1205-1211.
20. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.
21. Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003;21:2268-2275.
22. American Joint Committee on Cancer. Cancer Staging Manual. 5th ed. Philadelphia, Pa: Lippincott Raven; 1997.
23. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885-892.
24. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104-110.
25. Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin. 2003; 53:227-244.
26. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000;18:1412-1422.
27. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636-4642.
28. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
29. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol. 2000;18:1709-1717.
30. Desch CE, Hillner BE, Smith TJ, Retchin SM. Should the elderly receive chemotherapy for node-negative breast cancer? a cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol. 1993;11:777-782.
31. Kimmick GG, Muss HB. Systemic therapy for older women with breast cancer. Oncology (Huntingt). 2001; 15:280-291.